



## **XTCY Announces Extension of Management Cease Trade Order**

**Vancouver April 2, 2024 - XTACY THERAPEUTICS CORP. (CSE: XTCY) (Frankfurt: O3X4) (OTCQB: XTCYF) (“Xtacy Therapeutics” or the “Company”)** announces today the further to its news release of January 30, 2024, the Management Cease Trade Order (“MCTO”) issued by the British Columbia Securities Commission (“BCSC”) on January 30, 2024 remains in effect.

The MCTO prohibits the CEO and CFO and the Board of the Company from trading in the securities of the Company until such time as it has filed the following continuous disclosure documents (collectively, the “Documents”):

- the Company’s Annual Audited Financial Statements for the year ended September 30, 2023 and the Interim Financial Statements for the period ended December 31, 2023, as required by section 4.2 of National Instrument 51-102 - Continuous Disclosure Obligations NI 51-102”); and
- the Company’s Management Discussion Analysis (“MD&A”) for the year ended December 31, 2023, and the Interim MD&A for the period ended December 31, 2023, as required by section 5.1(2) of NI 51-102.
- CEO and CFO certificates relating to the Audited Annual and Interim Financial Statements, as required by NI 51-102

The Corporation is still working with its auditors and expects that the Documents will be filed by April 12, 2024 , and that the interim Q1 financial statements for the period ended December 31, 2023, will be filed by April 17, 2024.

During this period of default, the Company will continue to satisfy the provisions of the alternative information guidelines as required by National Policy 12-203 - Management Cease Trade Orders.

Xtacy confirms that, other than as disclosed in prior press releases and material change reports, there have been no material business developments since the filing on August 21, 2023, of the Company’s latest interim financial reports (Q3) for the period ended June 30, 2023.

### **About Xtacy Therapeutics Corp.:**

Xtacy Therapeutics Corp. is a prospect generator that provides high growth companies with financial, operational, and management assistance in the fast growing market for wellness consumer products. The focus of the Company is on global wellness, psychedelics, mycology, hemp and CBD, healthcare-related target companies.

**For further information visit websites:**

[www.xtacytherapeutics.com](http://www.xtacytherapeutics.com)

---

Or Contact Meris Kott CEO 604.484.0355 or email to [info@xtacytherapeutics.com](mailto:info@xtacytherapeutics.com)

Further information about the Company is available on [www.SEDAR.com](http://www.SEDAR.com) under the Company's profile.

Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.

Certain statements contained in this release may constitute "forward-looking statements" or "forward-looking information" (collectively "forward-looking information") as those terms are used in the Private Securities Litigation Reform Act of 1995 and similar Canadian laws. These statements relate to future events or future performance. The use of any of the words "could", "intend", "expect", "believe", "will", "projected", "estimated", "anticipates" and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on the Company's current belief or assumptions as to the outcome and timing of such future events. Actual future results may differ materially. In particular, this release contains forward-looking information relating to the business of the Company, its financing and certain corporate changes. The forward-looking information contained in this release is made as of the date hereof and the Company is not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. Because of the risks, uncertainties and assumptions contained herein, investors should not place undue reliance on forward-looking information. The foregoing statements expressly qualify any forward-looking information contained herein.